MS diagnostic bacterial identification library
MS diagnostic bacterial identification library
批准号:
8722128
负责人:
Robert K Ernst
金额:
$27.74万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2018-08-31
关键词:
Amino Acid SequenceAntibioticsBacteriaBacterial InfectionsBar CodesBiologicalBiological AssayBronchoalveolar Lavage FluidCell WallChemicalsClinicalDataData SetDevelopmentDiagnosisDiagnosticDiagnostic ProcedureFailureFingerprintFutureGenerationsGrowthHourIndividualInfectionIntellectual PropertyLaboratoriesLibrariesLifeLipidsMALDI-TOF Mass SpectrometryMass Spectrum AnalysisMembraneMembrane LipidsMethodologyMethodsMicrobeMorbidity - disease rateMycosesNucleic AcidsOrganismOutcomePathogen detectionPatientsPatternPeptide Sequence DeterminationPhenotypePhysiciansPreparationProtein AnalysisProteinsProtocols documentationRecoveryResistance profileResistance to infectionRibosomal ProteinsSample SizeSamplingSerumSolidSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSpeedStructureTechnologyTimeTranslatingUnited States Food and Drug Administrationantimicrobial peptidebaseclinically relevantcostculture platesdesignfundamental researchfungusgenome sequencingimprovedinterestmicrobialmicrowave electromagnetic radiationmortalitynovelnovel diagnosticspathogenpublic health relevanceresearch and developmenttreatment planningvaccine developmentwound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Rapid and accurate pathogen detection and identification is needed to allow physicians to react and respond
appropriately to potentially life threatening infections. With an increased need to treat life-threatening infections
more rapidly, in hours instead of days, improved assays using state-of-the-art technologies that decrease time,
diagnosis sample size, and cost per assay are needed. Current Food and Drug Administration (FDA)-approved
methods for pathogen detection in a clinical laboratory include biological culture, nucleic acid amplification,
ribosomal protein sequence characterization, or genome sequencing. Collectively, these methods suffer from
being time intensive, requiring amplification of clinically obtained material, and are often significantly costly and
burdensome for diagnostic laboratory support staff.
Recent advances in matrix-assisted laser desorption ionization-time of flight-mass spectrometry (MALDI-
TOF-MS) have enabled development of an accurate, and precise method for pathogen identification. The
method uses extracts containing high abundance proteins, picked directly from colonies on culture plates as a
chemical bar code for individual species to detect differences in the composition of ribosomal proteins with
~90% accuracy. To increase the ability to rapidly diagnose bacterial infections using MALDI-TOF-MS, this
proposal will develop, refine, and utilize ultra-small scale lipid purification methodologies for the extraction of
high abundance lipids from Gram-positive and -negative bacteria, as well as fungi. Essential, high abundance
lipids are found in all membranes of these microbes and are a highly diverse set of molecules. This diversity
forms the basis of our hypothesis that "essential bacterial and fungal lipids constitute a chemical barcode that
can be used to identify pathogens by mass spectrometry profiling". Our preliminary data show that these lipid
structures are unique and can be used as novel chemical barcodes for speciation and/or sub-speciation of
bacterial and fungal infections and resistance patterns to a subset of antibiotic and antimicrobial peptides.
Following a rapid extraction method, lipids will be analyzed by mass spectrometry and the resulting spectra will
be used to generate a mass spectral signature library of lipid "fingerprints" from a wide variety of clinically
relevant pathogen backgrounds. When combined, the analysis of the protein and lipid phenotype will provide >
99% accuracy in pathogen identification from a variety of samples, such as solid medium, serum,
bronchoalveolar lavage fluid and/or wound effluent. Ultimately, treatment plans tailored to specific infections
should translate to improved outcomes, such as faster recovery times, decreased complications, and
decreased morbidity and mortality infected patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
-
批准号:10722599
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2023
-
负责人:Robert K Ernst
-
依托单位:
Mid-Atlantic Microbial Pathogenesis Meeting 2022
-
批准号:10504721
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2022
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10116273
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10356152
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10570981
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants
-
批准号:9753900
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2016
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8650788
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8511015
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8675799
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8584054
-
项目类别:
-
资助金额:$18.04万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Bacterial Lipopolysaccharide Structure
-
批准号:7637607
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2008
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7476478
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7681139
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7911766
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7147812
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7254098
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
海外基金